Former Google DeepMind researcher Bilal Chughtai warned on July 14 that artificial intelligence development poses existential risks to humanity, stating that we do not have much time left. Chughtai, who resigned in July after working on artificial general intelligence safety and alignment, joins a growing wave of industry insiders raising alarms about the rapid race toward superintelligence.
Ex-Google Researcher Bilal Chughtai Raises Safety Alarms
Bilal Chughtai published statements on X and LinkedIn detailing his firsthand observations of development practices inside Google. According to Bloomberg, Chughtai worked specifically on alignment research, which designs systems to match human intentions and values.
“I directly observed how AI development proceeds at Google, and I too am extremely concerned about the basic direction this technology is headed,” Chughtai wrote on July 14. “I sincerely believe that AI has the potential to kill us, and that we do not have much time left.”
Chughtai warned that companies could build superintelligent AI systems surpassing human capabilities across all domains within the next few years. Because ensuring human intent remains a challenge, he noted that society might permanently lose command, potentially culminating in human extinction in the worst-case scenario. Chughtai suggested that averting these dangers calls for joint efforts to slow down a heated AI competition, while emphasizing the necessity for a broader group of people to boost openness in AI creation and carefully consider making sure AI serves human well-being.
Industry Departures and Leadership Warnings
Chughtai’s departure follows a similar exit earlier this month by Jacob Coxon, an AI developer who left Anthropic. Coxon criticized the rivalry between Anthropic and OpenAI, stating they are gambling with our lives as they race toward superintelligent AI. Coxon warned that many of the most aggressive scenarios are moving toward becoming reality and that the situation may already be out of control by the end of next year.
Concerns have also reached executive suites. Anthropic CEO Dario Amodei urged in a statement and a blog post that the speed of AI development needs to be adjusted to prevent advanced AI from escaping human control and leading to catastrophic outcomes. In an unusual show of agreement, OpenAI CEO Sam Altman and Elon Musk, who leads the AI business at SpaceX, expressed support and sympathy with Amodei’s concerns.
Despite these warnings from engineers and executives, political resistance remains. U.S. President Donald Trump dismissed demands for regulation from the AI industry, calling them “a scam.”
Balancing Innovation with Alignment Research
While Chughtai expressed severe concern over the trajectory of superintelligence, he believes there is still an opportunity to steer AI in a safer direction. Reports indicate he plans to continue focusing on AI safety.
- PPP Chief Criticizes President Lee’s ₩52B Overseas Tour Budget Cuts to Alliance Funds
- How to Protect Yourself From AI Scams: McAfee+ Guide
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- China’s spy agency warns of AI risk to national security (newsylist.com)